Concentration(s) Common formulations:- **PT-141 Injectable:** 10 mg/mL reconstituted solution- **Sermorelin Injectable:** 3 mg/mL, 6 mg/mL, 9 mg/mL- **GHK-Cu Topical:** 0.1% 3%- **NAD+ Injectable:** 100 mg/mL 500 mg/mL- **Oral Troche (PT-141, Sermorelin, NAD+):** 0.5-2 mg per dose Maximum Dosage (Day, Wk) Recommended maximum doses:- **PT-141:** 1.75 mg subcutaneous per dose, max 2 doses per week- **Sermorelin:** 200-500 mcg subcutaneous per dose, daily- **GHK-Cu:** Apply 1-2 times daily- **NAD+:** 50-500 mg subcutaneous per dose, 1-3x per week Contraindications Pregnancy, breastfeeding, active cancer, history of pituitary tumors, cardiovascular disease (for PT-141), history of melanoma (for GHK-Cu), uncontrolled hypertension, or hypersensitivity to any of the compounds

The American Red Cross and other major blood banks do not list GLP-1 receptor agonists as disqualifying medications, though you must still meet general health requirements including weight minimums, adequate hemoglobin levels, and proper hydration
They depend on which problems would disrupt your life the most
Well work with you to create a timeline that aligns perfectly with your recovery and performance goals
A candidate reference method for determination of total protein in serum